A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
The objective of this project was to develop a cell based in vitro experimental procedure that can differentiate P-glycoprotein (P-gp) substrates from inhibitors in a single assay. Caco-2 cells grown to confluency on 12-well Transwell were used for this study. The efflux permeability (B to A) of P-gp specific probe (viz., digoxin) in the presence of test compounds (e.g. substrates, inhibitors and non-substrates of P-gp) was monitored, and the influx permeability (A to B) of test compounds was evaluated after complete P-gp blockade. Radiolabelled digoxin was added on the basolateral side with buffer on the apical side. The digoxin concentration appearing on the apical side represents digoxin efflux permeability during the control phase (0-1 h period). After 1 h, a test compound (10 microM) was added on the apical side. The reduced efflux permeability of digoxin suggests that the added test compound is an inhibitor. The influx permeability of test compound is also determined during the 1-2 h study period by measuring the concentration of the test compound in the basolateral side. At the end of 2 h, a potent P-gp inhibitor (GF120918) was added. The increased influx permeability of test compound during the 2-3 h incubation period indicates that the added test compound is a substrate. Samples were taken from both sides at the end of 1-3 h and the concentrations of the test compounds and digoxin were quantitated. Digoxin efflux permeability remained unchanged when incubated with P-gp substrates (e.g., etoposide, rhodamine123, taxol). However, when a P-gp inhibitor was added to the apical side, the digoxin efflux (B to A permeability) was significantly reduced (ketoconazole=51% reduction) as expected. The influx permeability of substrates increased significantly (rhodamine123=70%, taxol=220%, digoxin=290%) after the P-gp inhibitor (GF120918) was introduced, whereas the influx permeability of P-gp inhibitor and non-substrates was not affected by GF120918. Thus, this combined assay provides an efficient cell based in vitro screening tool to simultaneously distinguish compounds that are P-gp substrates from P-gp inhibitors.
Balimane
Praveen V
PV
Metabolism and Pharmacokinetics, Bristol-Myers Squibb, P.O. Box # 4000, Mailstop:F.13-07, Route 206, Province Line Road, Princeton, NJ 08543, USA. Praveen.balimane@bms.com
Chong
Saeho
S
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000166:Acridines / Q000494:pharmacology; D018938:Caco-2 Cells; D002316:Cardiotonic Agents / Q000378:metabolism; D002463:Cell Membrane Permeability; D004077:Digoxin / Q000378:metabolism; D005079:Excipients; D006801:Humans; D007202:Indicators and Reagents; D012015:Reference Standards; D015203:Reproducibility of Results; D044005:Tetrahydroisoquinolines / Q000494:pharmacology
D018435:ATP Binding Cassette Transporter, Subfamily B; D000166:Acridines; D002316:Cardiotonic Agents; D005079:Excipients; D007202:Indicators and Reagents; D044005:Tetrahydroisoquinolines; D004077:Digoxin; C083501:Elacridar